|Articles|October 7, 2021
Supplements and Featured Publications
- Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease
Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease
Advertisement
This publication was funded and developed by United Therapeutics.
This AJMC® Clinical Brief summarizes results of the pivotal study by Aaron Waxman MD, PhD, et al published in The New England Journal of Medicine on the safety and efficacy of inhaled treprostinil in patients with pulmonary hypertension due to interstitial lung disease.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
NYC Nurses Strike Enters Day 5 Amid Staffing, Safety, and Benefit Disputes
2
5 FAQs About ICHRAs: What to Know as ACA Subsidy Extensions Stall
3
Long-term CR Seen With Allo-CAR-NK Cell Therapy Plus Rituximab in Waldenstrom NHL
4
Anti-Inflammatory, Antioxidant-Rich Diets May Lower Skin Cancer Risk, Slow Biological Aging
5

























































